Histone demethylase JMJD3 downregulation protects against aberrant force-induced osteoarthritis through epigenetic control of NR4A1.
10.1038/s41368-022-00190-4
- Author:
Yu JIN
1
,
2
,
3
,
4
;
Zhen LIU
1
,
2
,
3
,
4
;
Zhenxia LI
1
,
2
,
3
,
4
;
Hairui LI
1
,
2
,
3
,
4
;
Cheng ZHU
1
,
2
,
3
,
4
;
Ruomei LI
1
,
2
,
3
,
4
;
Ting ZHOU
1
,
2
,
3
,
5
;
Bing FANG
1
,
2
,
3
,
6
Author Information
1. Department of Orthodontics, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine
2. College of Stomatology, Shanghai Jiao Tong University
3. National Center for Stomatology
4. National Clinical Research Center for Oral Diseases, Shanghai Key Laboratory of Stomatology, Shanghai, China.
5. National Clinical Research Center for Oral Diseases, Shanghai Key Laboratory of Stomatology, Shanghai, China. tingzhou_em@126.com.
6. National Clinical Research Center for Oral Diseases, Shanghai Key Laboratory of Stomatology, Shanghai, China. fangbing@sjtu.edu.cn.
- Publication Type:Journal Article
- MeSH:
Cartilage, Articular/pathology*;
Chondrocytes/metabolism*;
Down-Regulation;
Epigenesis, Genetic;
Humans;
Jumonji Domain-Containing Histone Demethylases/metabolism*;
Nuclear Receptor Subfamily 4, Group A, Member 1/metabolism*;
Osteoarthritis/pathology*;
RNA, Small Interfering/pharmacology*
- From:
International Journal of Oral Science
2022;14(1):34-34
- CountryChina
- Language:English
-
Abstract:
Osteoarthritis (OA) is a prevalent joint disease with no effective treatment strategies. Aberrant mechanical stimuli was demonstrated to be an essential factor for OA pathogenesis. Although multiple studies have detected potential regulatory mechanisms underlying OA and have concentrated on developing novel treatment strategies, the epigenetic control of OA remains unclear. Histone demethylase JMJD3 has been reported to mediate multiple physiological and pathological processes, including cell differentiation, proliferation, autophagy, and apoptosis. However, the regulation of JMJD3 in aberrant force-related OA and its mediatory effect on disease progression are still unknown. In this work, we confirmed the upregulation of JMJD3 in aberrant force-induced cartilage injury in vitro and in vivo. Functionally, inhibition of JMJD3 by its inhibitor, GSK-J4, or downregulation of JMJD3 by adenovirus infection of sh-JMJD3 could alleviate the aberrant force-induced chondrocyte injury. Mechanistic investigation illustrated that aberrant force induces JMJD3 expression and then demethylates H3K27me3 at the NR4A1 promoter to promote its expression. Further experiments indicated that NR4A1 can regulate chondrocyte apoptosis, cartilage degeneration, extracellular matrix degradation, and inflammatory responses. In vivo, anterior cruciate ligament transection (ACLT) was performed to construct an OA model, and the therapeutic effect of GSK-J4 was validated. More importantly, we adopted a peptide-siRNA nanoplatform to deliver si-JMJD3 into articular cartilage, and the severity of joint degeneration was remarkably mitigated. Taken together, our findings demonstrated that JMJD3 is flow-responsive and epigenetically regulates OA progression. Our work provides evidences for JMJD3 inhibition as an innovative epigenetic therapy approach for joint diseases by utilizing p5RHH-siRNA nanocomplexes.
